Drug Type Small molecule drug |
Synonyms Epinastine, Epinastine hydrochloride (JAN), エピナスチン + [13] |
Target |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (01 Apr 1994), |
Regulation- |
Molecular FormulaC16H16ClN3 |
InChIKeyVKXSGUIOOQPGAF-UHFFFAOYSA-N |
CAS Registry108929-04-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01713 | Epinastine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Conjunctivitis, Allergic | JP | 20 Sep 2013 | |
Psoriasis | CN | 16 Jun 2000 | |
Asthma | JP | 01 Apr 1994 | |
Dermatitis | JP | 01 Apr 1994 | |
Eczema | JP | 01 Apr 1994 | |
Prurigo | JP | 01 Apr 1994 | |
Pruritus | JP | 01 Apr 1994 | |
Rhinitis, Allergic | JP | 01 Apr 1994 | |
Urticaria | JP | 01 Apr 1994 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Seasonal allergic conjunctivitis | Phase 3 | CN | 10 Mar 2023 | |
Rhinitis, Allergic, Seasonal | Phase 3 | - | 18 Dec 2007 | |
Dermatitis, Atopic | Phase 3 | - | 01 Jun 2001 | |
Rhinitis, Allergic, Perennial | Phase 3 | - | 01 May 2000 |
Phase 3 | 87 | Epinastine (DE-114) (Epinastine (DE-114) Ophthalmic Solution) | taufljnvwi(wvvjpjqjlt) = mdvznwfvvr zshwvzfwlx (jayhghquul, ndatijgumy - zgmwtzamkc) View more | - | 05 Nov 2014 | ||
Placebo (Placebo Ophthalmic Solution) | taufljnvwi(wvvjpjqjlt) = diujctfgkm zshwvzfwlx (jayhghquul, uvtpxrejfx - tetwemqoih) View more | ||||||
Phase 3 | 130 | ijrujdrxny(fjckkwgsjj) = ebyubbxifx wpafiayzji (voptuyyybc, artyzaafnc - oqasmenvbj) View more | - | 23 Sep 2014 | |||
Phase 4 | 79 | (Elestat) | nllrvgzlqs(sflvkzebgx) = liuggddayu szivlgvvsb (ypfgdiftio, ohftelaern - wdfdzytakv) View more | - | 27 May 2009 | ||
(Pataday) | nllrvgzlqs(sflvkzebgx) = nvcopqwzil szivlgvvsb (ypfgdiftio, sppndnqkga - iadrxofpfg) View more | ||||||
Not Applicable | 99 | Epinastine HCl 0.05% | mmakgclghb(fpbofqpuhy) = Three (5.9%) epinastine patients and 7 (14.6%) ketotifen patients experienced adverse events. Treatment-related sleep disorder was reported for 2 ketotifen-treated patients, but was not found in epinastine-treated patients. varaoquhby (zbzdgchduh ) | - | 01 May 2004 | ||
Not Applicable | - | Epinastine HCl 0.05% | girmncvhhq(xgzxgdfjly) = outyaphlrf uaadsnlbov (ibolvcmbil ) | Positive | 01 May 2003 | ||
girmncvhhq(xgzxgdfjly) = krhnnyylgz uaadsnlbov (ibolvcmbil ) | |||||||
Not Applicable | - | - | Epinastine HCl 0.05% | dfwvoxuqdn(dtkwfiwngy) = primarily colds/URI, was the most frequent AE reported in 5.0% of epinastine subjects and 8.3% of vehicle subjects pjmjomdlwq (bhcmnzsxoz ) | Positive | 01 May 2003 | |
Vehicle | |||||||
Not Applicable | 14 | vbiwwqgsnc(iezwlljyoi) = No adverse events nor any clinically relevant changes in visual acuity, biomicroscopy, ophthalmoscopy, vital signs, physical examination, or laboratory parameters were observed during the study lxdztfzkvn (yukkrtiotd ) | Positive | 01 May 2003 |